Elamipretide (SS-31) Clinical Evidence: Phase 2 Data and What It Shows

SS-31 (Szeto-Schiller 31 — the tetrapeptide D-Arg-2'6'-dimethylTyr-Lys-Phe-NH2; developed by Hazel Szeto at Weill Cornell Medicine; licensed to Stealth BioTherapeutics for clinical development under the name elamipretide; selectively concentrates at the inner mitochondrial membrane by binding to cardiolipin, the unique dimeric phospholipid that anchors electron transport chain (ETC) complexes) has an unusual development story that differs from most research peptides.

Most research peptides are studied initially in preclinical models and then potentially in human exploratory studies. SS-31/elamipretide progressed through a full pharmaceutical development pipeline: preclinical studies in multiple disease models, Phase 1 safety and pharmacokinetics in healthy volunteers, and multiple Phase 2 efficacy trials in rare disease populations where the mitochondrial mechanism had the clearest biological rationale. This is drug development, not informal research — and the resulting clinical data is of higher quality than most research peptide human studies.

The three primary clinical programs were in Barth syndrome (a rare X-linked genetic disorder of cardiolipin metabolism), heart failure with reduced ejection fraction (HFrEF), and primary mitochondrial disease. Each program addressed a different aspect of the cardiolipin-ETC biology that SS-31 targets.

Barth syndrome (a rare X-linked genetic disorder caused by mutations in the tafazzin gene, which encodes an enzyme required for normal cardiolipin remodeling; characterized by cardiomyopathy, skeletal muscle weakness, neutropenia, and growth retardation in affected boys; the cardiolipin abnormality that causes Barth syndrome is the most direct possible target for a cardiolipin-binding therapeutic) is the disease where SS-31/elamipretide has the most mechanistically direct rationale: the disease is literally a cardiolipin disorder, and the drug works by binding and stabilizing cardiolipin.

Published Phase 2 data in Barth syndrome subjects showed measurable improvements in exercise capacity (measured by the 6-minute walk distance), skeletal muscle strength, and patient-reported functional outcomes. The FDA granted Rare Pediatric Disease designation and Orphan Drug designation to elamipretide for Barth syndrome, reflecting the unmet medical need and the mechanistically compelling rationale.

The Barth syndrome program represents the cleanest translational story in the elamipretide clinical data: a genetic defect in cardiolipin metabolism → a compound that stabilizes cardiolipin → documented improvement in cardiolipin-dependent mitochondrial function → functional improvement in affected patients. This causal chain is rarely this mechanistically clean in drug development.

The PROGRESS-HF (Phase 2 Randomized Open-label study of subcutaneous elamipretide in patients with Heart Failure with Reduced Ejection Fraction — the Phase 2 trial that examined subcutaneous elamipretide in HFrEF patients with documented mitochondrial dysfunction markers) trial examined elamipretide in a larger and more commercially important population than Barth syndrome: patients with established heart failure.

Heart failure was selected as a target because published research had documented cardiolipin loss and ETC dysfunction in failing human cardiac tissue — creating the same mechanistic rationale as in Barth syndrome, though through acquired rather than genetic cardiolipin pathology. Published data from PROGRESS-HF showed that elamipretide treatment produced measurable improvements in left ventricular end systolic volume (LVESV — a measure of cardiac remodeling and a surrogate marker for cardiac functional recovery) compared to placebo at the 28-week primary endpoint.

However, the magnitude of the LVESV improvement, while statistically significant, was modest compared to the effect sizes seen with established heart failure therapies like sacubitril-valsartan. Whether the structural cardiac improvement produced by elamipretide translates to the clinical outcomes that matter for patients (reduced hospitalizations, reduced mortality) was not determined by the Phase 2 study — which was powered for the surrogate endpoint, not the clinical outcomes.

Primary mitochondrial disease (a heterogeneous group of inherited disorders caused by mutations in either nuclear DNA or mitochondrial DNA genes encoding ETC subunits or assembly factors; affecting approximately 1 in 5,000 people; producing a wide spectrum of multisystem disease affecting tissues with high energy demand including heart, brain, muscle, and liver) represents a broader indication where mitochondrial-targeting therapy has potential application.

Published Phase 2 elamipretide data in primary mitochondrial disease included patients with multiple mitochondrial DNA and nuclear DNA-encoded ETC defects. The primary endpoints were exercise capacity and patient-reported outcomes. Published results showed improvements in exercise capacity (six-minute walk distance) and patient-reported fatigue and function in a subset of subjects.

The primary mitochondrial disease program was complicated by the heterogeneity of the patient population — different genetic mutations cause different patterns of ETC dysfunction, and a cardiolipin-stabilizing approach might be expected to benefit patients with ETC complex organization problems more than those with specific subunit mutations that cardiolipin stabilization cannot address. The mixed results in this population may partly reflect this mechanistic heterogeneity.

Cardiolipin (the unique dimeric phospholipid found almost exclusively in the inner mitochondrial membrane; essential for the structural organization and function of ETC complexes I, III, IV, and V; levels decline with age, in heart failure, and in multiple mitochondrial disease states; measurable in tissue biopsies and, with specialized techniques, in circulating blood cells) was proposed as an efficacy biomarker in elamipretide clinical trials — a measure of whether the drug was hitting its molecular target.

Published studies from the elamipretide program documented that elamipretide treatment altered cardiolipin composition in accessible tissues, specifically normalizing the ratio of mature (remodeled) to immature (unremodeled) cardiolipin species. This normalization is mechanistically meaningful: healthy mitochondria have a specific cardiolipin fatty acid composition that is maintained by the tafazzin enzyme; disease states produce abnormal cardiolipin composition that impairs ETC function.

The cardiolipin biomarker data provides the most direct molecular evidence that elamipretide is engaging its proposed target in human subjects — not just producing functional changes that could be attributed to non-specific effects. This target engagement data is important for mechanistic interpretation of the clinical results and for designing future studies where cardiolipin normalization can be used as a pharmacodynamic measure of drug exposure.

Stealth BioTherapeutics pursued a Phase 3 program for Barth syndrome (the TAZPOWER trial) that was powered for the primary clinical endpoint of 6-minute walk distance. The published primary analysis of TAZPOWER did not meet the pre-specified primary endpoint for statistical significance, which was a setback for the Barth syndrome indication and contributed to substantial challenges for the company.

This outcome illustrates an important general principle about translational medicine: Phase 2 trials showing signals on surrogate endpoints do not guarantee Phase 3 success on clinical endpoints. The 6-minute walk improvement seen in Phase 2 Barth syndrome patients did not reproduce at the magnitude needed for statistical significance in the larger Phase 3 study. Whether this reflects the natural variability of the rare disease population, the specific primary endpoint choice, or a genuine limitation of elamipretide's efficacy in this context is debated in the published literature.

For researchers studying SS-31 outside the clinical context, the Phase 2 clinical data remains the best available human evidence for the cardiolipin-targeting mechanism. The clinical development setback does not negate the preclinical mechanistic data or the Phase 2 signals — it contextualizes them as preliminary evidence that requires further investigation rather than established efficacy.

SS-31/elamipretide has the most advanced clinical evidence base of any peptide commonly studied in the research peptide community. Multiple Phase 2 trials with published data, a Phase 3 trial, FDA rare disease designations, and years of institutional pharmaceutical development represent a qualitatively different evidence level than most compounds available for research use.

The Phase 3 setback in Barth syndrome should not be misinterpreted as evidence that the mitochondrial mechanism is wrong or that SS-31 has no biological activity. Phase 3 trials fail for many reasons beyond insufficient biological activity — endpoint selection, sample size, patient heterogeneity, timing of treatment, and statistical design all play roles. The underlying mechanistic data and Phase 2 signals remain.

For researchers designing SS-31 protocols, the published clinical data provides important protocol guidance: subcutaneous administration was used in the published clinical trials (at doses of 4-40 mg per day in the clinical programs), and the primary measured endpoints (exercise capacity, cardiolipin composition, mitochondrial function markers) provide a validated outcome framework. Researchers can anchor their studies in this published clinical precedent while exploring mechanistic questions that the clinical trials were not designed to address.

Researchers studying mitochondrial biology, cardiolipin function, and cellular bioenergetics can review SS-31 product specifications at Blackwell BioLabs. All batches are verified by third party testing with HPLC purity confirmation and mass spectrometry identity verification on every lot. Certificates of Analysis are available for every batch.